文献速递妇科

激素治疗对卵巢子宫内膜异位囊肿的影响:系统综述与Meta分析

The Effect of Hormonal Treatment on Ovarian Endometriomas: A Systematic Review and Meta-Analysis.
PubMed 文献 · J Minim Invasive Gynecol · 2024-01-06

本系统综述与Meta分析纳入16项研究共888例接受激素治疗至少3个月的绝经前子宫内膜异位症患者,评估激素抑制对卵巢子宫内膜异位囊肿体积的影响。结果显示6个月时囊肿体积平均缩小55%(95%CI -40至-71,p<.001,I²=96%),以地诺孕素和炔诺酮醋酸酯联合来曲唑缩小最明显,复方激素避孕药或其他孕激素无统计学显著缩小。

要点

  • 激素抑制治疗6个月时子宫内膜异位囊肿体积平均缩小55%(95%CI -40至-71,p<.001)。
  • 地诺孕素与炔诺酮醋酸酯联合来曲唑的囊肿缩小幅度最大,其次为relugolix和亮丙瑞林。
  • 复方激素避孕药或其他孕激素未见统计学显著的体积缩小。

核心结论

  • 激素抑制可显著缩小子宫内膜异位囊肿体积,但患者实际缩小幅度存在不确定性。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、PubMed、Cochrane Central Register of Controlled Trials、Embase和ClinicalTrials.gov从2012年1月至2022年12月。
  • 纳入16项研究(15项队列研究、1项随机对照试验),共888例接受激素治疗至少3个月的绝经前子宫内膜异位症患者。
  • 排除随访期间接受手术干预的研究以及使用激素预防子宫内膜异位症术后囊肿复发的研究。
  • 采用纽卡斯尔-渥太华量表和Cochrane偏倚风险工具评估偏倚风险。
  • 方案已在PROSPERO注册(CRD42022385612)。

主要发现

  • 主要结局为基线与至少6个月时子宫内膜异位囊肿体积的平均变化百分比。
  • 全球范围内,6个月时囊肿体积平均缩小55%(95%CI -40至-71;18个治疗组;730例患者;p<.001;I²=96%),差异有统计学意义。
  • 地诺孕素和炔诺酮醋酸酯联合来曲唑的缩小幅度最大,其次为relugolix和亮丙瑞林。
  • 复方激素避孕药或其他孕激素的体积缩小无统计学意义。
  • 次要结局为3个月时体积变化及按激素治疗类别分析。

关键数值与推荐

  • 地诺孕素(7项研究)、其他孕激素(4项)、复方激素避孕药(2项)、其他抑制治疗(3项)。
  • 6个月时囊肿体积平均缩小55%(95%CI -40至-71;18个治疗组;730例患者;p<.001;I²=96%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 异质性高(I²=96%)。
  • 研究存在选择偏倚风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effect of hormonal suppression of endometriosis on the size of endometriotic ovarian cysts. DATA SOURCES: The authors searched MEDLINE, PubMed, Cochrane Central Register of Controlled Trials, Embase, and ClinicalTrials.gov from January 2012 to December 2022. METHODS OF STUDY SELECTION: We included studies of premenopausal women undergoing hormonal treatment of endometriosis for ≥3 months. The authors excluded studies involving surgical intervention in the follow-up period and those using hormones to prevent endometrioma recurrence after endometriosis surgery. Risk of bias was assessed with the Newcastle-Ottawa Scale and Cochrane Risk of Bias Tool. The protocol was registered in PROSPERO (CRD42022385612). TABULATION, INTEGRATION, AND RESULTS: The primary outcome was the mean change in endometrioma volume, expressed as a percentage, from baseline to at least 6 months. Secondary outcomes were the change in volume at 3 months and analyses by class of hormonal therapy. The authors included 16 studies (15 cohort studies, 1 randomized controlled trial) of 888 patients treated with dienogest (7 studies), other progestins (4), combined hormonal contraceptives (2), and other suppressive therapy (3). Globally, the decrease in endometrioma volume became statistically significant at 6 months with a mean reduction of 55% (95% confidence interval, -40 to -71; 18 treatment groups; 730 patients; p <.001; I2 = 96%). The reduction was the greatest with dienogest and norethindrone acetate plus letrozole, followed by relugolix and leuprolide acetate. The volume reduction was not statistically significant with combined hormonal contraceptives or other progestins. There was high heterogeneity, and studies were at risk of selection bias. CONCLUSION: Hormonal suppression can substantially reduce endometrioma size, but there is uncertainty in the exact reduction patients may experience.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Thiel PS, Donders F, Kobylianskii A, et al. The Effect of Hormonal Treatment on Ovarian Endometriomas: A Systematic Review and Meta-Analysis. J Minim Invasive Gynecol. 2024. PMID: 38190884. doi:10.1016/j.jmig.2024.01.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。